MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Olema Oncology, Inc. Common Stock
OLMA
|
+$14.2M |
| 2 |
Morphic Holding, Inc. Common Stock
MORF
|
+$10.5M |
| 3 |
Cymabay Therapeutics
CBAY
|
+$8.1M |
| 4 |
Structure Therapeutics
GPCR
|
+$7.44M |
| 5 |
Viking Therapeutics
VKTX
|
+$4.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$47.8M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$38.6M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$23.9M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$5.52M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$1.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$667M
| $69.2M | 18.48% |
7,648,268
| – | – |
2021 Q1
10 quarters
|
|
|
2
Olema Oncology, Inc. Common Stock
OLMA
$662M
| $22.9M | 6.12% |
1,857,681
+1,395,181
| +302% | +$14.2M |
2023 Q2
1 quarter
|
|
3
Geron
GERN
$623M
| $22.7M | 6.06% |
10,712,481
+1,521,191
| +17% | +$4.13M |
2021 Q3
8 quarters
|
|
4
DELISTED
Repare Therapeutics
RPTX
| $19.8M | 5.29% |
1,639,849
| – | – |
2020 Q2
13 quarters
|
|
5
DELISTED
iTeos Therapeutics
ITOS
| $19.1M | 5.1% |
1,745,943
| – | – |
2020 Q3
12 quarters
|
|
6
Intellia Therapeutics
NTLA
$1.36B
| $17.2M | 4.6% |
544,639
| – | – |
2021 Q3
8 quarters
|
|
7
MoonLake Immunotherapeutics
MLTX
$1.06B
| $16.8M | 4.48% |
294,190
-921
| -0.3% | -$50.8K |
2023 Q2
1 quarter
|
|
8
Iovance Biotherapeutics
IOVA
$3.59B
| $15M | 3.99% |
3,287,397
+337,279
| +11% | +$2.2M |
2022 Q2
5 quarters
|
|
9
DELISTED
Crinetics Pharmaceuticals
CRNX
| $14.2M | 3.8% |
479,053
| – | – |
2021 Q3
8 quarters
|
|
10
Insmed
INSM
$26.6B
| $13.3M | 3.56% |
527,458
-2,285
| -0.4% | -$52.3K |
2022 Q4
3 quarters
|
|
|
11
Structure Therapeutics
GPCR
$1.43B
| $11.6M | 3.11% |
+230,761
| New | +$7.44M |
2023 Q3
0 quarters
|
|
12
DELISTED
Verve Therapeutics
VERV
| $11.4M | 3.04% |
857,940
| – | – |
2022 Q3
4 quarters
|
|
13
Relay Therapeutics
RLAY
$4B
| $11.4M | 3.04% |
1,352,133
-2,235
| -0.2% | -$24K |
2023 Q1
2 quarters
|
|
14
Regenxbio
RGNX
$505M
| $10.8M | 2.89% |
656,718
| – | – |
2022 Q3
4 quarters
|
|
|
15
DELISTED
Cymabay Therapeutics
CBAY
| $9.11M | 2.43% |
+610,770
| New | +$8.1M |
2023 Q3
0 quarters
|
|
16
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9M | 2.4% |
53,210
-189
| -0.4% | -$35.5K |
2023 Q2
1 quarter
|
|
17
DELISTED
Amicus Therapeutics
FOLD
| $8.71M | 2.32% |
716,139
+200,000
| +39% | +$2.58M |
2021 Q3
8 quarters
|
|
18
Revolution Medicines
RVMD
$37.3B
| $7.57M | 2.02% |
273,408
| – | – |
2021 Q3
8 quarters
|
|
19
Xeris Biopharma Holdings
XERS
$3.04B
| $7.42M | 1.98% |
3,987,967
+12,968
| +0.3% | +$29.7K |
2023 Q2
1 quarter
|
|
|
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.84M | 1.83% |
664,224
+279,234
| +73% | +$3.74M |
2023 Q2
1 quarter
|
|
21
Axsome Therapeutics
AXSM
$7.45B
| $6.54M | 1.75% |
93,586
| – | – |
2022 Q4
3 quarters
|
|
22
Madrigal Pharmaceuticals
MDGL
$9.9B
| $5.97M | 1.59% |
40,859
+2,848
| +7% | +$536K |
2022 Q2
5 quarters
|
|
|
23
DELISTED
KalVista Pharmaceuticals
KALV
| $5.57M | 1.49% |
577,958
-183,580
| -24% | -$1.88M |
2023 Q2
1 quarter
|
|
24
Werewolf Therapeutics
HOWL
$47.6M
| $5.11M | 1.36% |
2,388,011
| – | – |
2021 Q2
9 quarters
|
|
25
Travere Therapeutics
TVTX
$4.86B
| $4.94M | 1.32% |
552,846
| – | – |
2021 Q3
8 quarters
|
|
Similar funds
MPM BioImpact's Q3 2023 Portfolio in Review
As of Q3 2023, MPM BioImpact held 38 positions worth $375M, down 25% from $497M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
MPM BioImpact withdrew a net $59.9M in Q3 2023, closing 6 positions and reducing 6 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $47.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM BioImpact opened a new position in Morphic Holding, Inc. Common Stock worth $4.58M.
- MPM BioImpact's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 200,000 shares worth $4.58M.
- MPM BioImpact added most to Olema Oncology, Inc. Common Stock in Q3 2023, an estimated $14.2M increase.
- MPM BioImpact's biggest Q3 2023 reduction was KalVista Pharmaceuticals, cutting an estimated $1.88M.
- MPM BioImpact fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
- MPM BioImpact's ten largest holdings make up 61% of its $375M portfolio in Q3 2023.
- MPM BioImpact opened 4 new positions and closed 6 in Q3 2023.
- MPM BioImpact's portfolio value fell 25% quarter-over-quarter to $375M.
Based on MPM BioImpact's 13F filing for Q3 2023, filed 14 Nov 2023.